Cargando...
Biomarkers and Surrogate Endpoints: How and When might They Impact Drug Development?
As the pharmaceutical industry starts developing novel molecules developed based on molecular biology principles and a better understanding of the human genome, it becomes increasingly important to develop early indicators of activity and/or toxicity. Biomarkers are measurements based on molecular p...
Gardado en:
| Autor Principal: | |
|---|---|
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado: |
IOS Press
2002
|
| Assuntos: | |
| Acceso en liña: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3850863/ https://ncbi.nlm.nih.gov/pubmed/12364814 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1155/2002/438745 |
| Tags: |
Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!
|